cagrilintide appetite suppressant Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide 5mg Peptide | Puratek

This is consistent with the peptides origin in gastric juice and its role in protecting and rebuilding the digestive lining

Animal studies show it reduces inflammation in colitis models, heals intestinal anastomoses (surgical connections), reverses intestinal perforations, and protects the gut lining from NSAID damage

Their products are top of the line

Potential theoretical advantages include: Multi-pathway appetite suppression combining amylin and incretin signals Enhanced metabolic flexibility through glucagon receptor activation (retatrutide) and amylin-mediated effects (cagrilintide) Complementary gastric emptying effects from both compounds Broader receptor coverage addressing multiple aspects of energy homeostasis However, it's critical to emphasize: no published clinical trials have evaluated the cagrilintide dosage with retatrutide combination as of 2026